About TearClear
TearClear is a Healthcare company based in Copley Township (United States) founded in 2015. Filter technology for preservative-free ophthalmic drugs is developed. TearClear has raised $31.98 million across 5 funding rounds from investors including Falcon Vision, Visionary Ventures and Bluestem. Its focus areas include Life Sciences, Ophthalmology, Drugs and Glaucoma. Its legal entity is TEARCLEAR CORP. Its competitors include Qlaris Bio, Aria Pharmaceuticals and Altheos; 3 of its 3 listed competitors have raised funding.
Company details
TearClear was founded in 2015 in Copley Township, United States, within the biotechnology sector focused on ophthalmic treatments. A chemical filter technology is being developed to remove benzalkonium chloride at the point of drug instillation, enabling safe preservation of multi-dose products for glaucoma, dry-eye, and allergic conjunctivitis therapies until application. Operations center on advancing this delivery method for topical ophthalmic drugs.
- Headquarters Copley Township, United States
- SectorsHealthcare
- Website tearclear.com
- Social LinkedIn X
- Legal Name Tearclear Corp.
- Total Equity Funding$31.98M (USD)
in 5 rounds
- Latest Funding Round$5.9M (USD), Debt – Conventional
Aug 2022
- InvestorsFalcon Vision
& 3 more
Funding Insights of TearClear
TearClear has successfully raised a total of $31.98M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $5.9 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.98M
- Total Rounds 5
- Last Round Debt – Conventional — $5.9M
- First Round $4.63M
(May 2017)
- Investors Count 4
All 5 funding rounds of TearClear with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $5.9M | Debt – Conventional | – | – | – |
| Aug 2020 | $22.35M | Series B | – | Falcon Vision, Flying L Partners | |
| Feb 2020 | $2.79M | Debt – Conventional | – | – | – |
| Feb 2019 | $5M | Series A | – | – | – |
| May 2017 | $4.63M | Series A | – | Visionary Ventures, Bluestem Capital | – |
4 investors in total: 4 institutional.
Investors in TearClear
TearClear has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Falcon Vision, Visionary Ventures and Bluestem.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital fund focused on life sciences investments. | 2019 | visionaryvc.com | Newport Beach, United States | |
Bluestem is recognized as a Midwest private equity company. | bluestemcapital.com | Sioux Falls, United States | ||
Flying L Partners is focused on ophthalmic sector investments. | flyinglpartners.com | |||
| falconvision.com |
Investor details for TearClear
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TearClear
3 dated milestones of TearClear across 7 years, from founding to its latest funding, stage changes and deals.
- Founded TearClear is founded.
- Funding First funding round of $4.6M.
- Funding Latest funding round, Debt – Conventional, of $5.9M.
Competitors of TearClear
TearClear has 3 listed competitors in our database, 3 of them funded. They include Qlaris Bio, Aria Pharmaceuticals and Altheos.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qlaris.bio | 2019 | United States | $49.03M | AI-based technology is developed for treating ophthalmic diseases. | ||
| ariapharmaceuticals.com | 2015 | Palo Alto, United States | $14.31M | Develops innovative drug technologies for multiple diseases. | ||
| altheos.com | 2010 | San Francisco, United States | $32.5M | Focuses on R&D and manufacturing of drugs for various therapeutic areas. |
Detailed competitors of TearClear
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as TearClear (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tearclear
Complete news archive for TearClear
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TearClear
TearClear was founded in 2015 and raised its 1st funding round 2 years after it was founded.
TearClear is headquartered in Copley Township, United States. It is registered at Copley Township, Ohio, United States.
TearClear is a funded company, having raised a total of $31.98M across 5 funding rounds to date. The company's 1st funding round was a Series A of $4.63M, raised on May 2017.
TearClear was founded in 2015 in Copley Township, United States, within the biotechnology sector focused on ophthalmic treatments. A chemical filter technology is being developed to remove benzalkonium chloride at the point of drug instillation, enabling safe preservation of multi-dose products for glaucoma, dry-eye, and allergic conjunctivitis therapies until application. Operations center on advancing this delivery method for topical ophthalmic drugs.
TearClear's top competitors include Qlaris Bio, Aria Pharmaceuticals and Altheos.
TearClear has 4 investors. Key investors include Falcon Vision, Visionary Ventures, Bluestem, and Flying L Partners.
TearClear operates through Tearclear Corp..